˾»ú ÃæÒé ÊÕ²Ø ÉêÇëְλ
Ê×Ò³ > Ì©ÖÝÕÐÆ¸ > ˾»ú

˾»ú

Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾

Ë¢ÐÂÓÚ£º2020-09-21±»ä¯ÀÀ£º1705´Î

ÃæÒé

²»ÏÞ / ¸ßÖÐ / ÐÔ±ð²»ÏÞ / 1 / ²»ÏÞµ½¸Ú

½­ËÕ-Ì©ÖÝ £¨Ì©ÖÝÒ½Ò©¸ßм¼Êõ²úÒµÔ°¿Ú̩·Î÷²à½¼Ò·¶«²àG79´± £© Éϰà·Ïß²éѯ

ÕÐÆ¸1

³Â
ְλ·¢²¼ÈË£º³ÂÏÈÉú

139****6549,052****713092 ÏÔʾºÅÂë

(ÁªÏµÊ±Çë˵Ã÷ÊÇÔÚÐÂÌ©ÖÝÈ˲ÅÍøÉÏ¿´µ½µÄ)

´òµç»°Ç°ÏÈͶ¸ö¼òÀú£¬»ñµÃÃæÊԵijɹ¦ÂÊÔö¼Ó30%

Ì©ÖÝÈ˲ÅÍøÌáʾ£ºÌ©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÎÞȨÊÕÈ¡ÈκηÑÓã¬Çë¹ã´óÇóÖ°Õß¼ÓÇ¿×ÔÎÒ±£»¤Òâʶ£¬°´ÀͶ¯·¨¹æ±£»¤×ÔÉíÈ¨Òæ£¬¾¯ÌèÐé¼ÙÕÐÆ¸,±ÜÃâÉϵ±ÊÜÆ­£¡ ¾Ù±¨´Ëְλ
ְλÃèÊö

ÈÎÖ°ÒªÇó£º1³ÖC1ÒÔÉϼÝÖ¤£¬ÊìϤÖܱ߳ÇÊн»Í¨Çé¿ö£¬ÎÞ¼ÝÊ»°²È«ÔðÈÎʹʡ£
2ÈýÄêÒÔÉÏÏà¹Ø¹¤×÷¾­Ñ飬ÄÜÊÊÓ¦¼Ó°àºÍÖܱ߳ÇÊгö²î°²ÅÅ¡£
3ÉíÌ彡¿µ£¬ÄܳԿàÄÍÀÍ£¬·þÎñÒâʶǿ£¬Óм«Ç¿ÔðÈÎÐÄ£¬ÍËÎé¾üÈËÓÅÏÈ¡£
¹¤×÷Ö°Ôð£º1¸ºÔð¹«Ë¾µÄÈÕ³£Ó󵣬±£Ö¤³µÁ¾×´¿öÁ¼ºÃ²¢°´Ê±°²È«³ö³µ¡£
2¸ºÔð³µÁ¾µÄÈÕ³£Çå½à£¬ÊìϤ³µÁ¾µÄ±£ÏÕÑé³µ±£ÑøÎ¬Ð޵ȹ¤×÷¡£
3°´¹æ¶¨×öºÃÐгµ¼Ç¼¡£
4Íê³ÉÁìµ¼½»°ìµÄÆäËû¹¤×÷ÈÎÎñ¡£

¹«Ë¾¼ò½é
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÓÚ2015ÄêÈëפ̩ÖÝÊÐÖйúÒ½Ò©³Ç£¬×¢²á×ʱ¾2000ÍòÃÀÔª¡£¹«Ë¾Ö÷Òª´Óʵ¥¿¹Ò©ÎïÉú²ú£¬Í¶×Ê×ܶî2ÒÚÃÀÔª£¬Ä⽨³§·¿Ãæ»ý3ÍòÓàÆ½·½£¬½¨Éè·ûºÏGMP±ê×¼µÄ¹ú¼ÊÏȽøµÄ¿¹ÌåÒ©ÎïÖÆ±¸Ìåϵ£¬ÒÔÆÚ´òÔì¹úÄÚ¿¹ÌåÒ©ÎïÉú²ú¸ßµØ¡£Âõ²©Ì«¿ÆÒ©ÒµÓÉÉϺ£ÕŽ­ÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾£¨¿¹ÌåÒ©ÎïÓë°ÐÏòÖÎÁƹú¼ÒÖØµãʵÑéÊÒ£©¿¹ÌåÑз¢ÍŶÓÌṩһվʽƽ̨·þÎñ£¬ÖÂÁ¦ÓÚʵÏÖһϵÁÐÖØÁ¿¼¶¹ú¼Ò´´Ð¿¹ÌåÒ©ÎïµÄ²úÒµ»¯¡£ÏÖÓÐÆ·ÖÖ£ºÖÎÁƽáÖ±³¦°©µÄÖØ×鿹EGFRÈËÊóǶºÏµ¥¿Ë¡¿¹Ì壬ÖÎÁÆÒøÐ¼²¡µÄÖØ×éÈËLFA3-¿¹ÌåÈںϵ°°×µÈ¡£TaizhouMabtechPharmaceuticalCo.,Ltd.joinedtheChinaMedicalCity(CMC)in2015withregisteredcapitalofUSD20million,expandinganationalhighlandformonoclonalantibodymedicinemanufacturingbyestablishinginternationallyadvancedantibodymedicinemanufacturesystemwithadoptedcGMPstandards,withatotalinvestmentofUSD200million.Supportedbytheone-stopplatformfortherapeuticmAbmedicinedevelopmentprovidedbyZJ-BioR&DTeam(StateKeyLaboratoryofAntibodyMedicineandTargetedTherapy),TaizhouMabtechPharmaceuticsCo.,Ltdisdedicatedtoindustrializationofaseriesof¡°blockbuster¡±innovativeantibodydrugs.Existingvarieties:recombinantanti-EGFRhuman/mouse-chimericmonoclonalantibodyforthetreatmentofcolorectalcancer,recombinanthumanLFA3-antibodyfusionproteinforthetreatmentofpsoriasis,etal.
¸Ã¹«Ë¾µÄÆäTAְλ
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
  • ÖÆÔìÒµ
  • ÍâÉÌͶ×ÊÆóÒµ
  • ½­ËÕ-Ì©ÖÝ
  • 100-1000ÈË
0%¼òÀú·´À¡ÂÊ
0ƽ¾ù»Ø¸´Ê±³¤
0¸öÕÐÆ¸Ö°Î»
ְλÃû³Æ£ºË¾»ú
¹«Ë¾Ãû³Æ£º Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
 
ÏàËÆÖ°Î»
  • ²æ³µË¾»ú
    4ǧ6-5ǧ/Ô ̩ÖÝ-Ì©ÐË
    °®É­£¨Öйú£©ÐõÄý¼ÁÓÐÏÞ¹«Ë¾
  • ÃÅ»ú˾»ú
    7ǧ5-9ǧ/Ô ̩ÖÝ-Ì©ÐË
    Ì©ÐËÊкçÇŲִ¢ÓÐÏÞ¹«Ë¾
  • ×Ôж³µË¾»ú
    5ǧ-6ǧ/Ô ̩ÖÝ-Ì©ÐË
    ½­ËÕº¼¸»»·±£¿Æ¼¼ÓÐÏÞ¹«Ë¾
  • Ð)µË¾»ú
    ÃæÒé Ì©ÖÝ-Ì©ÐË
    ½­ËÕ¶¦ÍúÒ±½ð²ÄÁÏÓÐÏÞ¹«Ë¾